Ensaio em fase de recrutamento = ; Ensaio a decorrer = ; Financiado por um membro do IRDiRC = ; Membro de uma ERN =

Ensaio (s) clínico (s) nacional (is)

ESPANHA

Cataluña
BARCELONA

INFRONT-3: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene - ES

Hospital Clínic de Barcelona

Servicio de Neurología

Mais detalhes

ESPANHA

País Vasco
SAN SEBASTIÁN

INFRONT-3: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene - ES

Hospital Universitario Donostia

Servicio de Neurología

Mais detalhes

ITALIA

LOMBARDIA
BRESCIA

A Non-invasive, Multimodal Approach to Restore Functional Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia

IRCCS Centro S.Giovanni di Dio - Fatebenefratelli

Laboratorio di Epidemiologia e Neuroimaging LENITEM

Mais detalhes

REINO UNIDO

Greater London
LONDON

INFRONT: A First in Human Phase 1 Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin Mutation-GB

Joint UCLH/UCL Biomedical Research and Development (R&D) Unit

University College London (UCL) and University College London Hospitals NHS Trust (UCLH)

Mais detalhes

REINO UNIDO

Hampshire
SOUTHAMPTON

DeNDRoN 067 TRx-237-007: A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD) (phase III) - UK

Southampton General Hospital

Wessex Neurological Centre

Mais detalhes